S&P 500   3,632.76 (+1.54%)
DOW   30,041.92 (+1.52%)
QQQ   293.94 (+1.22%)
AAPL   115.05 (+1.05%)
MSFT   213.33 (+1.53%)
FB   274.32 (+2.19%)
GOOGL   1,758.03 (+1.76%)
AMZN   3,126.35 (+0.90%)
TSLA   546.82 (+4.78%)
NVDA   518.43 (-1.36%)
BABA   276.76 (+2.46%)
CGC   26.84 (+8.58%)
GE   10.50 (+4.27%)
MU   63.55 (-0.98%)
AMD   84.87 (-0.52%)
T   29.34 (+2.52%)
NIO   53.00 (-4.30%)
F   9.44 (+6.55%)
ACB   9.03 (+25.77%)
NFLX   479.17 (+0.54%)
GILD   60.80 (+1.52%)
BA   219.31 (+3.68%)
DIS   151.20 (+3.58%)
S&P 500   3,632.76 (+1.54%)
DOW   30,041.92 (+1.52%)
QQQ   293.94 (+1.22%)
AAPL   115.05 (+1.05%)
MSFT   213.33 (+1.53%)
FB   274.32 (+2.19%)
GOOGL   1,758.03 (+1.76%)
AMZN   3,126.35 (+0.90%)
TSLA   546.82 (+4.78%)
NVDA   518.43 (-1.36%)
BABA   276.76 (+2.46%)
CGC   26.84 (+8.58%)
GE   10.50 (+4.27%)
MU   63.55 (-0.98%)
AMD   84.87 (-0.52%)
T   29.34 (+2.52%)
NIO   53.00 (-4.30%)
F   9.44 (+6.55%)
ACB   9.03 (+25.77%)
NFLX   479.17 (+0.54%)
GILD   60.80 (+1.52%)
BA   219.31 (+3.68%)
DIS   151.20 (+3.58%)
S&P 500   3,632.76 (+1.54%)
DOW   30,041.92 (+1.52%)
QQQ   293.94 (+1.22%)
AAPL   115.05 (+1.05%)
MSFT   213.33 (+1.53%)
FB   274.32 (+2.19%)
GOOGL   1,758.03 (+1.76%)
AMZN   3,126.35 (+0.90%)
TSLA   546.82 (+4.78%)
NVDA   518.43 (-1.36%)
BABA   276.76 (+2.46%)
CGC   26.84 (+8.58%)
GE   10.50 (+4.27%)
MU   63.55 (-0.98%)
AMD   84.87 (-0.52%)
T   29.34 (+2.52%)
NIO   53.00 (-4.30%)
F   9.44 (+6.55%)
ACB   9.03 (+25.77%)
NFLX   479.17 (+0.54%)
GILD   60.80 (+1.52%)
BA   219.31 (+3.68%)
DIS   151.20 (+3.58%)
S&P 500   3,632.76 (+1.54%)
DOW   30,041.92 (+1.52%)
QQQ   293.94 (+1.22%)
AAPL   115.05 (+1.05%)
MSFT   213.33 (+1.53%)
FB   274.32 (+2.19%)
GOOGL   1,758.03 (+1.76%)
AMZN   3,126.35 (+0.90%)
TSLA   546.82 (+4.78%)
NVDA   518.43 (-1.36%)
BABA   276.76 (+2.46%)
CGC   26.84 (+8.58%)
GE   10.50 (+4.27%)
MU   63.55 (-0.98%)
AMD   84.87 (-0.52%)
T   29.34 (+2.52%)
NIO   53.00 (-4.30%)
F   9.44 (+6.55%)
ACB   9.03 (+25.77%)
NFLX   479.17 (+0.54%)
GILD   60.80 (+1.52%)
BA   219.31 (+3.68%)
DIS   151.20 (+3.58%)
Log in
NASDAQ:LYRA

Lyra Therapeutics Stock Forecast, Price & News

$12.89
+1.76 (+15.81 %)
(As of 11/24/2020 01:17 PM ET)
Add
Compare
Today's Range
$12.56
Now: $12.89
$13.45
50-Day Range
$10.58
MA: $11.46
$13.14
52-Week Range
$10.37
Now: $12.89
$22.00
Volume14,466 shs
Average Volume81,834 shs
Market Capitalization$166.63 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Lyra Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. The company's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. Its product candidates include LYR-210 and LYR-220, which are bioresorbable polymeric matrices for the treatment of chronic rhinosinusitis. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was founded in 2005 and is headquartered in Watertown, Massachusetts.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 3.2Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.63 out of 5 stars


Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:LYRA
CUSIPN/A
CIKN/A
Phone617-373-4600
Employees33

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Market Cap$166.63 million
Next Earnings Date2/9/2021 (Estimated)
OptionableNot Optionable
$12.89
+1.76 (+15.81 %)
(As of 11/24/2020 01:17 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive LYRA News and Ratings via Email

Sign-up to receive the latest news and ratings for LYRA and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Lyra Therapeutics (NASDAQ:LYRA) Frequently Asked Questions

Do Wall Street analysts recommend investors buy shares of Lyra Therapeutics?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Lyra Therapeutics in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Lyra Therapeutics
.

What stocks does MarketBeat like better than Lyra Therapeutics?

Wall Street analysts have given Lyra Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Lyra Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Lyra Therapeutics' next earnings date?

Lyra Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, February 9th 2021.
View our earnings forecast for Lyra Therapeutics
.

How were Lyra Therapeutics' earnings last quarter?

Lyra Therapeutics, Inc. (NASDAQ:LYRA) issued its earnings results on Tuesday, November, 10th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.41) by $0.08.
View Lyra Therapeutics' earnings history
.

What price target have analysts set for LYRA?

4 analysts have issued 12-month target prices for Lyra Therapeutics' shares. Their forecasts range from $21.00 to $28.00. On average, they anticipate Lyra Therapeutics' stock price to reach $24.33 in the next year. This suggests a possible upside of 89.2% from the stock's current price.
View analysts' price targets for Lyra Therapeutics
.

Who are some of Lyra Therapeutics' key competitors?

What other stocks do shareholders of Lyra Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Lyra Therapeutics investors own include Pfizer (PFE), DocuSign (DOCU), Intel (INTC), OPKO Health (OPK), Valero Energy (VLO), Advanced Micro Devices (AMD), CrowdStrike (CRWD), Gilead Sciences (GILD), Micron Technology (MU) and ONEOK (OKE).

Who are Lyra Therapeutics' key executives?

Lyra Therapeutics' management team includes the following people:
  • Dr. Maria Palasis Ph.D., Chair of the Board, CEO & Pres (Age 55, Pay $523.83k)
  • Mr. R. Donald Elsey, CFO, Treasurer & Sec. (Age 66, Pay $367.16k)
  • Dr. Carmichael S. Roberts Jr., Co-Founder (Age 52)
  • Mr. Ray Knox, VP of Operations
  • Ms. Corinne Noyes, Sr. VP of Commercial Strategy & Market Devel. (Age 52)
  • Ms. Vineeta Belanger Ph.D., Sr. VP of Clinical Affairs
  • Dr. Robert Richard Ph.D., Sr. VP of R&D
  • Ms. Pamela E. Nelson, Sr. VP of Regulatory Affairs
  • Mr. Robert M. Solomon, Assistant Sec.

When did Lyra Therapeutics IPO?

(LYRA) raised $52 million in an initial public offering on Friday, May 1st 2020. The company issued 3,500,000 shares at a price of $14.00-$16.00 per share. BofA Securities, Jefferies and William Blair served as the underwriters for the IPO and BTIG was co-manager.

What is Lyra Therapeutics' stock symbol?

Lyra Therapeutics trades on the NASDAQ under the ticker symbol "LYRA."

When did Lyra Therapeutics' lock-up period expire?

Lyra Therapeutics' lock-up period expired on Wednesday, October 28th. Lyra Therapeutics had issued 3,500,000 shares in its public offering on May 1st. The total size of the offering was $56,000,000 based on an initial share price of $16.00. Since the end of Lyra Therapeutics' lock-up period, restrictions preventing major shareholders and company insiders from selling shares in the company have been lifted.

Who are Lyra Therapeutics' major shareholders?

Lyra Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include ArrowMark Colorado Holdings LLC (6.10%), BlackRock Inc. (1.60%), State Street Corp (0.35%), Boothbay Fund Management LLC (0.34%), Nisa Investment Advisors LLC (0.13%) and New York State Common Retirement Fund (0.03%). Company insiders that own Lyra Therapeutics stock include Edward T Anderson and Polaris Venture Partners Speci.
View institutional ownership trends for Lyra Therapeutics
.

Which major investors are selling Lyra Therapeutics stock?

LYRA stock was sold by a variety of institutional investors in the last quarter, including New York State Common Retirement Fund. Company insiders that have sold Lyra Therapeutics company stock in the last year include Edward T Anderson, and Polaris Venture Partners Speci.
View insider buying and selling activity for Lyra Therapeutics
.

Which major investors are buying Lyra Therapeutics stock?

LYRA stock was bought by a variety of institutional investors in the last quarter, including ArrowMark Colorado Holdings LLC, Boothbay Fund Management LLC, Nisa Investment Advisors LLC, State Street Corp, and BlackRock Inc.. Company insiders that have bought Lyra Therapeutics stock in the last two years include Edward T Anderson, and Polaris Venture Partners Speci.
View insider buying and selling activity for Lyra Therapeutics
.

How do I buy shares of Lyra Therapeutics?

Shares of LYRA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Lyra Therapeutics' stock price today?

One share of LYRA stock can currently be purchased for approximately $12.86.

How big of a company is Lyra Therapeutics?

Lyra Therapeutics has a market capitalization of $166.24 million. Lyra Therapeutics employs 33 workers across the globe.

What is Lyra Therapeutics' official website?

The official website for Lyra Therapeutics is www.lyratherapeutics.com.

How can I contact Lyra Therapeutics?

Lyra Therapeutics' mailing address is 480 ARSENAL STREET, WATERTOWN MA, 02472. The company can be reached via phone at 617-373-4600 or via email at [email protected]

This page was last updated on 11/24/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.